Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.78 |
| ▸ | NQO2 | P16083 | 1/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801854 | 1.00 | MET (0.78) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL30733000 | 1.00 | MET (0.78) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL29517102 | 0.87 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL12486932 | 0.87 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL12489208 | 0.87 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL12690037 | 0.87 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL25426802 | 0.85 | MET (0.72) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL12487598 | 0.85 | MET (0.72) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL12689735 | 0.83 | MET (0.78) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL22109176 | 0.83 | MET (0.70) | METNQO2PDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515418-B1 | USE OF C-MET INHIBITORS TO TREAT CANCERS HARBOURING MET MUTATIONS | ASTRAZENECA AB (SE) | 2021-04-14 | — | — | EP | disclosed |
| US-20190282570-A1 | Use of c-Met Inhibitors to Treat Cancers Harbouring MET Mutations | ASTRAZENECA AB (SE) | 2019-09-19 | — | — | US | disclosed |
| WO-2018055029-A1 | USE OF C-MET INHIBITORS TO TREAT CANCERS HARBOURING MET MUTATIONS | ASTRAZENECA AB (SE) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282570-A1 | Use of c-Met Inhibitors to Treat Cancers Harbouring MET Mutations | MET, RET, MYC | MET 1/4885NQO2 3683/4885PDE4C 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.